Ardelyx (ARDX) Net Income towards Common Stockholders (2013 - 2026)
Ardelyx (ARDX) posted Net Income towards Common Stockholders of -$37.6 million for Q1 2026, down 9139.56% on a QoQ basis from -$407000.0 in Q4 2025, and up 8.6% year-over-year from -$34.6 million in Q1 2025.
Ardelyx (ARDX) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Ardelyx's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$37.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 8.6% year-over-year to -$37.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.1 million (down 7.99% YoY) and the FY2025 annual result came in at -$61.6 million, down 57.4% from the prior year.
- Net Income towards Common Stockholders was -$37.6 million for Q1 2026 at Ardelyx, down from -$407000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $10.7 million in Q4 2022 and bottomed at -$41.1 million in Q1 2025.
- A 5-year average of -$16.0 million and a median of -$19.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 129.52% — and 2023, when it slumped 369.3%.
- Ardelyx's Net Income towards Common Stockholders stood at $10.7 million in 2022, then tumbled by 369.3% to -$28.8 million in 2023, then surged by 116.13% to $4.6 million in 2024, then plunged by 108.76% to -$407000.0 in 2025, then plunged by 9139.56% to -$37.6 million in 2026.
- Business Quant data shows ARDX's Net Income towards Common Stockholders at -$37.6 million in Q1 2026, -$407000.0 in Q4 2025, and -$969000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | -37.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.61 Mn |
| Dec 31, 2025 | -407,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -41.14 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | -16.45 Mn |
| Mar 31, 2024 | -26.52 Mn |
| Dec 31, 2023 | -28.80 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -26.77 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -26.94 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -36.23 Mn |
| Sep 30, 2021 | -43.59 Mn |
| Jun 30, 2021 | -45.19 Mn |